CSPG4 and neoplasm: The anti-CSPG4 IgG1 constructs demonstrated the ability to mediate substantially effective antibody-dependent cellular phagocytosis (ADCP) in patient-derived monocytes and reduced tumour size in human melanoma xenograft models.